The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.

Abstract excerpt

Cancer immunotherapy has revolutionized oncology by leveraging the immune system to combat tumors. Among various biomarkers, neoantigens and tumor mutational burden (TMB) have emerged as critical factors in tailoring personalized treatments. Neoantigens are tumor-specific peptides displayed on cancer cell surfaces, derived from somatic mutations. Recognized as "non-self" by the immune system, they trigger T-cell...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antigens, Neoplasm
• Share to Biomarkers, Tumor